GO
Loading...

Pharmaceuticals

More

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • *Q1 sales 11.496 bln Swiss francs vs 11.887 bln forecast. ZURICH, April 15- Adverse currency moves weighed on first-quarter sales at Roche Holding AG, which fell 1 percent, despite a healthy uptake of its new cancer medicines.

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • Biotechs in the green after last week's carnage Monday, 14 Apr 2014 | 2:58 PM ET

    Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.

  • Report: Glaxo bribed doctors in Poland Monday, 14 Apr 2014 | 9:00 AM ET

    LONDON— The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. The British drug company faces corruption probes in China and Iraq.

  • *Allegations follow corruption accusations in China, Iraq. LONDON/ WARSAW, April 14- GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq.

  • April 10- Rite Aid Corp, the third-largest U.S. drugstore operator, forecast fiscal 2015 sales above analysts' estimates as it benefits from the launch of new generic drugs and enrolls more customers in its loyalty programs.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • Pfizer CEO worries about ACA coverage     Thursday, 10 Apr 2014 | 11:43 AM ET

    Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.

  • MUMBAI, April 10- India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • Alkermes is a true drug innovator: CEO     Thursday, 10 Apr 2014 | 8:21 AM ET

    Richard Pops, chairman & CEO of Alkermes, discusses Alkermes' new injectable drug for the treatment of schizophrenia. We have more psychiatry products in our pipeline, reveals Pops.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

  • Eli Lilly CEO: We keep investing in R&D     Thursday, 10 Apr 2014 | 6:51 AM ET

    John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.

  • Flu drug stockpiles a waste of money: Report Thursday, 10 Apr 2014 | 6:27 AM ET

    The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.

  • PARIS/ ZURICH, April 10- France's competition authority is investigating drugmakers Roche and Novartis on suspicion they were involved in anti-competitive practices in relation to eye disease treatments, the companies said on Thursday.

  • April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

  • MUMBAI, April 9- India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

Most Popular Video

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.

Thursday, 17 Apr 2014 | 11:00 AM ET

Phil LeBeau has the details on the latest rides at this year's New York Auto Show.

Monday, 14 Apr 2014 | 11:43 AM ET

Dr. Steven Horng, Beth Israel Deaconess Medical Center, explains how Google Glass provided crucial support in an emergency situation and helped save a life.